Sickle Cell Disease - Pipeline Review, H1 2018

  • ID: 4529321
  • Report
  • 211 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • bluebird bio Inc
  • CSL Ltd
  • Gamida Cell Ltd
  • Intellia Therapeutics Inc
  • Morphogenesis Inc
  • MORE
Sickle Cell Disease - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H1 2018, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

Report Highlights:

This latest pipeline guide Sickle Cell Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 6, 10, 29, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4 and 2 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • bluebird bio Inc
  • CSL Ltd
  • Gamida Cell Ltd
  • Intellia Therapeutics Inc
  • Morphogenesis Inc
  • MORE
Introduction

Sickle Cell Disease - Overview

Sickle Cell Disease - Therapeutics Development

Sickle Cell Disease - Therapeutics Assessment

Sickle Cell Disease - Companies Involved in Therapeutics Development

Sickle Cell Disease - Drug Profiles

Sickle Cell Disease - Dormant Projects

Sickle Cell Disease - Product Development Milestones

Appendix

List of Tables

Table 1: Number of Products under Development for Sickle Cell Disease, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Universities/Institutes, H1 2018

Table 6: Products under Development by Companies, H1 2018

Table 7: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 8: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 9: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 10: Products under Development by Universities/Institutes, H1 2018

Table 11: Number of Products by Stage and Target, H1 2018

Table 12: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 13: Number of Products by Stage and Mechanism of Action, H1 2018

Table 14: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 15: Number of Products by Stage and Route of Administration, H1 2018

Table 16: Number of Products by Stage and Molecule Type, H1 2018

Table 17: Sickle Cell Disease - Pipeline by Acceleron Pharma Inc, H1 2018

Table 18: Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H1 2018

Table 19: Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, H1 2018

Table 20: Sickle Cell Disease - Pipeline by ArQule Inc, H1 2018

Table 21: Sickle Cell Disease - Pipeline by Bio Products Laboratory Ltd, H1 2018

Table 22: Sickle Cell Disease - Pipeline by Bioverativ Inc, H1 2018

Table 23: Sickle Cell Disease - Pipeline by bluebird bio Inc, H1 2018

Table 24: Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H1 2018

Table 25: Sickle Cell Disease - Pipeline by Calimmune Inc, H1 2018

Table 26: Sickle Cell Disease - Pipeline by CRISPR Therapeutics, H1 2018

Table 27: Sickle Cell Disease - Pipeline by CSL Ltd, H1 2018

Table 28: Sickle Cell Disease - Pipeline by Editas Medicine Inc, H1 2018

Table 29: Sickle Cell Disease - Pipeline by Epizyme Inc, H1 2018

Table 30: Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC, H1 2018

Table 31: Sickle Cell Disease - Pipeline by Fulcrum Therapeutics Inc, H1 2018

Table 32: Sickle Cell Disease - Pipeline by Gamida Cell Ltd, H1 2018

Table 33: Sickle Cell Disease - Pipeline by Genethon SA, H1 2018

Table 34: Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H1 2018

Table 35: Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H1 2018

Table 36: Sickle Cell Disease - Pipeline by Incyte Corp, H1 2018

Table 37: Sickle Cell Disease - Pipeline by Intellia Therapeutics Inc, H1 2018

Table 38: Sickle Cell Disease - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018

Table 39: Sickle Cell Disease - Pipeline by La Jolla Pharmaceutical Company, H1 2018

Table 40: Sickle Cell Disease - Pipeline by MaxCyte Inc, H1 2018

Table 41: Sickle Cell Disease - Pipeline by Merck & Co Inc, H1 2018

Table 42: Sickle Cell Disease - Pipeline by MimeTech Srl, H1 2018

Table 43: Sickle Cell Disease - Pipeline by Morphogenesis Inc, H1 2018

Table 44: Sickle Cell Disease - Pipeline by NKT Therapeutics Inc, H1 2018

Table 45: Sickle Cell Disease - Pipeline by Novartis AG, H1 2018

Table 46: Sickle Cell Disease - Pipeline by Orphagen Pharmaceuticals Inc, H1 2018

Table 47: Sickle Cell Disease - Pipeline by Oryzon Genomics SA, H1 2018

Table 48: Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, H1 2018

Table 49: Sickle Cell Disease - Pipeline by Protagonist Therapeutics Inc, H1 2018

Table 50: Sickle Cell Disease - Pipeline by ReveraGen BioPharma Inc, H1 2018

Table 51: Sickle Cell Disease - Pipeline by Sancilio & Company Inc, H1 2018

Table 52: Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, H1 2018

Table 53: Sickle Cell Disease - Pipeline by Syros Pharmaceuticals Inc, H1 2018

Table 54: Sickle Cell Disease - Dormant Projects, H1 2018

Table 55: Sickle Cell Disease - Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 56: Sickle Cell Disease - Dormant Projects, H1 2018 (Contd..2), H1 2018

List of Figures

Figure 1: Number of Products under Development for Sickle Cell Disease, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 8: Number of Products by Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acceleron Pharma Inc
  • Angiocrine Bioscience Inc
  • Annexin Pharmaceuticals AB
  • ArQule Inc
  • Bio Products Laboratory Ltd
  • Bioverativ Inc
  • bluebird bio Inc
  • Bristol-Myers Squibb Co
  • Calimmune Inc
  • CRISPR Therapeutics
  • CSL Ltd
  • Editas Medicine Inc
  • Epizyme Inc
  • Errant Gene Therapeutics LLC
  • Fulcrum Therapeutics Inc
  • Gamida Cell Ltd
  • Genethon SA
  • Gilead Sciences Inc
  • Global Blood Therapeutics Inc
  • Incyte Corp
  • Intellia Therapeutics Inc
  • Ironwood Pharmaceuticals Inc
  • La Jolla Pharmaceutical Company
  • MaxCyte Inc
  • Merck & Co Inc
  • MimeTech Srl
  • Morphogenesis Inc
  • NKT Therapeutics Inc
  • Novartis AG
  • Orphagen Pharmaceuticals Inc
  • Oryzon Genomics SA
  • Prolong Pharmaceuticals LLC
  • Protagonist Therapeutics Inc
  • ReveraGen BioPharma Inc
  • Sancilio & Company Inc
  • Sangamo Therapeutics Inc
  • Syros Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll